BR0215288A - Composto, sais farmaceuticamente aceitáveis do mesmo, e, métodos para identificar células tumorais ricas em receptores de p2x7, purinérgicos em um mamìfero, para tratar de uma condição médica em um mamìfero, e para induzir a apoptose em células neoplásticas em um paciente - Google Patents
Composto, sais farmaceuticamente aceitáveis do mesmo, e, métodos para identificar células tumorais ricas em receptores de p2x7, purinérgicos em um mamìfero, para tratar de uma condição médica em um mamìfero, e para induzir a apoptose em células neoplásticas em um pacienteInfo
- Publication number
- BR0215288A BR0215288A BR0215288-6A BR0215288A BR0215288A BR 0215288 A BR0215288 A BR 0215288A BR 0215288 A BR0215288 A BR 0215288A BR 0215288 A BR0215288 A BR 0215288A
- Authority
- BR
- Brazil
- Prior art keywords
- mammal
- pharmaceutically acceptable
- methods
- acceptable salts
- receptors
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 241000124008 Mammalia Species 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 3
- 102100037602 P2X purinoceptor 7 Human genes 0.000 title abstract 2
- 101710189965 P2X purinoceptor 7 Proteins 0.000 title abstract 2
- 210000004881 tumor cell Anatomy 0.000 title abstract 2
- 230000006907 apoptotic process Effects 0.000 title 1
- 210000005170 neoplastic cell Anatomy 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Saccharide Compounds (AREA)
Abstract
"COMPOSTO SAIS FARMACEUTICAMENTE ACEITáVEIS DO MESMO, E, MéTODOS PARA IDENTIFICAR CéLULAS TUMORAIS RICAS EM RECEPTORES DE P2X~ 7~ PURINéRGICOS EM UM MAMìFERO, PARA TRATAR DE UMA CONDIçãO MéDICA EM UM MAMìFERO, E PARA INDUZIR A APOPTOSE EM CéLULAS NEOPLáSTICAS EM UM PACIENTE". A presente invenção refere-se a derivados de tirosila e seus sais farmaceuticamente aceitáveis; composições destes e métodos para preparar os compostos são descritos. Os compostos são úteis no tratamento de doenças em mamíferos que são mediados pela ação do receptor de P2X~ 7~.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34297701P | 2001-12-21 | 2001-12-21 | |
PCT/US2002/041385 WO2003059353A1 (en) | 2001-12-21 | 2002-12-23 | Tyrosyl derivatives and their use as p2x7 receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0215288A true BR0215288A (pt) | 2004-12-21 |
Family
ID=23344134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0215288-6A BR0215288A (pt) | 2001-12-21 | 2002-12-23 | Composto, sais farmaceuticamente aceitáveis do mesmo, e, métodos para identificar células tumorais ricas em receptores de p2x7, purinérgicos em um mamìfero, para tratar de uma condição médica em um mamìfero, e para induzir a apoptose em células neoplásticas em um paciente |
Country Status (14)
Country | Link |
---|---|
US (1) | US7094895B2 (pt) |
EP (1) | EP1487449A4 (pt) |
JP (1) | JP2005517684A (pt) |
KR (1) | KR20040096508A (pt) |
CN (1) | CN1617725A (pt) |
AU (1) | AU2002361864A1 (pt) |
BR (1) | BR0215288A (pt) |
CA (1) | CA2471562A1 (pt) |
IL (1) | IL162653A0 (pt) |
MX (1) | MXPA04006123A (pt) |
NZ (1) | NZ533649A (pt) |
RU (1) | RU2004122409A (pt) |
WO (1) | WO2003059353A1 (pt) |
ZA (1) | ZA200405327B (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1473367E (pt) * | 2003-04-17 | 2007-09-10 | Affectis Pharmaceuticals Ag | Meios e processos para o diagnóstico e tratamento de distúrbios afectivos |
US20090220516A1 (en) * | 2005-06-22 | 2009-09-03 | Alan Laties | Neuroprotection of retinal ganglion cells |
US8200164B2 (en) | 2005-12-01 | 2012-06-12 | Intel Corporation | Wireless communication system, associated methods and data structures |
FR2912145B1 (fr) * | 2007-02-02 | 2009-03-06 | Servier Lab | Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
EA022505B1 (ru) | 2008-03-25 | 2016-01-29 | Эффектис Фармасьютиклз Аг | Новые p2x7r антагонисты и их применение |
PT2243772E (pt) | 2009-04-14 | 2012-03-28 | Affectis Pharmaceuticals Ag | Novos antagonistas de p2x7r e sua utilização |
JP2013526496A (ja) | 2010-05-14 | 2013-06-24 | アフェクティス ファーマシューティカルズ アーゲー | P2x7r拮抗剤の新規調製方法 |
WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
RS55532B1 (sr) | 2012-03-16 | 2017-05-31 | Vitae Pharmaceuticals Inc | Modulatori jetrenog x receptora |
NZ629122A (en) | 2012-03-16 | 2016-04-29 | Vitae Pharmaceuticals Inc | Liver x receptor modulators |
EP2989104B1 (en) * | 2013-04-23 | 2019-08-21 | Esteve Pharmaceuticals, S.A. | Pyrazino[1,2-a]indole compounds, their preparation and use in medicaments |
FR3043555B1 (fr) * | 2015-11-17 | 2019-10-25 | Centre National De La Recherche Scientifique (Cnrs) | Mirabegron pour le traitement de maladies retiniennes |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5245034A (en) * | 1988-12-26 | 1993-09-14 | Kiroyoshi Hidaka | Compound having vessel smooth muscle relaxation activity |
CA2005741C (en) * | 1988-12-26 | 1998-06-02 | Hiroyoshi Hidaka | Quinoline sulfonoamino compounds having vessel smooth muscle relaxation activity |
JPH069402A (ja) * | 1991-05-15 | 1994-01-18 | Hiroyoshi Hidaka | 抗潰瘍剤 |
US6916812B2 (en) * | 2001-10-09 | 2005-07-12 | Bristol-Myers Squibb Company | Alpha-aminoamide derivatives as melanocortin agonists |
WO2003047515A2 (en) * | 2001-11-30 | 2003-06-12 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | P2x7 receptor antagonists |
-
2002
- 2002-12-23 EP EP02797493A patent/EP1487449A4/en not_active Withdrawn
- 2002-12-23 MX MXPA04006123A patent/MXPA04006123A/es unknown
- 2002-12-23 AU AU2002361864A patent/AU2002361864A1/en not_active Abandoned
- 2002-12-23 JP JP2003559515A patent/JP2005517684A/ja active Pending
- 2002-12-23 US US10/329,094 patent/US7094895B2/en not_active Expired - Fee Related
- 2002-12-23 CN CNA028278127A patent/CN1617725A/zh active Pending
- 2002-12-23 CA CA002471562A patent/CA2471562A1/en not_active Abandoned
- 2002-12-23 IL IL16265302A patent/IL162653A0/xx unknown
- 2002-12-23 KR KR10-2004-7009910A patent/KR20040096508A/ko not_active Application Discontinuation
- 2002-12-23 NZ NZ533649A patent/NZ533649A/en unknown
- 2002-12-23 WO PCT/US2002/041385 patent/WO2003059353A1/en not_active Application Discontinuation
- 2002-12-23 RU RU2004122409/04A patent/RU2004122409A/ru not_active Application Discontinuation
- 2002-12-23 BR BR0215288-6A patent/BR0215288A/pt not_active IP Right Cessation
-
2004
- 2004-07-05 ZA ZA200405327A patent/ZA200405327B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
RU2004122409A (ru) | 2005-04-10 |
CN1617725A (zh) | 2005-05-18 |
ZA200405327B (en) | 2005-07-05 |
EP1487449A1 (en) | 2004-12-22 |
EP1487449A4 (en) | 2006-08-23 |
AU2002361864A1 (en) | 2003-07-30 |
US20030181452A1 (en) | 2003-09-25 |
JP2005517684A (ja) | 2005-06-16 |
IL162653A0 (en) | 2005-11-20 |
CA2471562A1 (en) | 2003-07-24 |
KR20040096508A (ko) | 2004-11-16 |
WO2003059353A1 (en) | 2003-07-24 |
NZ533649A (en) | 2006-01-27 |
MXPA04006123A (es) | 2004-11-01 |
US7094895B2 (en) | 2006-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0215288A (pt) | Composto, sais farmaceuticamente aceitáveis do mesmo, e, métodos para identificar células tumorais ricas em receptores de p2x7, purinérgicos em um mamìfero, para tratar de uma condição médica em um mamìfero, e para induzir a apoptose em células neoplásticas em um paciente | |
BR0209147A (pt) | Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais | |
BR0315337A (pt) | Composto, formulação farmacêutica, e, método para tratar câncer | |
BR0111548A (pt) | Derivados bicìclicos substituìdos para o tratamento de crescimento de célula anormal | |
BRPI0412899A (pt) | composto para inibir a atividade de parp, usos de uma quantidade terapêutica e uma quantidade terapeuticamente efetiva de um composto e de seus sais farmaceuticamente aceitáveis, uso de um composto, composição farmacêutica, e, método para o tratamento de cáncer em mamìferos | |
BR9913319A (pt) | Composições e métodos para tratamento de doenças mitocondriais | |
BR0316685A (pt) | Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade | |
NO20075042L (no) | Farmasoytisk sammensetning innbefattende en omega-karboksyarylsubstituert difenylurea for behandling av cancer | |
NO20045005L (no) | Fremgangsmate for behandling av arytmier som omfatter administrering av en A1-adenosinagonist med en betablokker, kalsiumkanalblokker eller et hjerteglykosid | |
CY1105199T1 (el) | Θepαπευτικες συνθεσεις για αντιμετωπιση της υπepεκκρισης βλεννας | |
BR9908030A (pt) | Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado | |
BRPI0313942B8 (pt) | derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas | |
UA81629C2 (ru) | Применение композиции и способ лечения инфекционных заболеваний крупного рогатого скота и свиней | |
BR9709959A (pt) | Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas | |
CR8380A (es) | Metodos para preparar y utilizar compuestos novedosos de celulas madre y sus conjuntos | |
BR0314308A (pt) | Composto, composição farmacêutica, métodos para bloquear uma combinação de mu, kappa, delta ou receptor (heterodìmero) dos mesmos em mamìferos, para tratar ou prevenir obesidade e doenças relacionadas, para suprimir o apetite em um paciente em necessidade deste, e para realizar a perda de peso em um paciente obeso, e, uso de um composto | |
BR0306919A (pt) | Métodos para reduzir ou suprimir a efetividade adversa da terapia de l-dopa e/ou do agonista da dopamina, e para tratamento moderado de l-dopa, composição para tratamento moderado de l-dopa, método para tratar doença de parkinson e/ou complicações motoras de l-dopa, composição para o tratamento da doença de parkinson, e, métodos para prolongar o tratamento eficaz da doença de parkinson, e para tratar os distúrbios de movimento | |
BR9909474A (pt) | Formas ii, cristalina e v de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, solvato de etanol de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, composição, composto, uso de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol, e, processos para o tratamento de uma infecção viral em um humano e para a produção de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil -1h-benzimidazol | |
HK1071310A1 (en) | Combination therapy for the treatment of cancer | |
BRPI0415249A (pt) | terapia de combinação para infecção por hcv | |
IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
BR0313718A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto | |
BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
BR9908510A (pt) | Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana | |
BR9910179A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para tratar uma doença ou condição mediada por fator xa em um animal de sangue quente |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A,6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2034 DE 29/12/2009. |